ZNF281 Emerges as a Novel Driver and Therapeutic Target in Advanced Prostate Cancer

/in /by

ZNF281 is a Krüppel-type zinc-finger transcription factor previously implicated in cancer stemness, but its role in prostate cancer has remained largely unexplored. In a new study, researchers evaluated ZNF281 expression across human prostate cancer samples, including primary tumors, metastatic lymph nodes, and normal prostate tissue. The findings revealed significantly higher expression of ZNF281 in metastatic […]

Read more

NRG1-Driven Microenvironmental Resistance to PI3K Inhibition in Prostate Cancer

/in /by

Prostate cancer is driven not only by tumor genetics but also by dynamic interactions with the tumor microenvironment (TME). Although alterations in the PI3K pathway are common, especially in PTEN-deficient disease, clinical results with PI3K inhibitors, even when combined with androgen receptor (AR) blockade, have been underwhelming. New evidence suggests that resistance may be driven […]

Read more

Arginase 1 Suppression Makes Exercise Effective Against Prostate Cancer

/in /by

Exercise has consistently been linked to improved outcomes in prostate cancer, but the mechanisms behind this effect have remained unclear. A recent preclinical study provides a compelling explanation, identifying suppression of arginase 1 (Arg1) and modulation of arginine metabolism as key drivers of exercise-induced tumor control. Using a prostate-specific Pten-knockout mouse model, researchers observed that […]

Read more

IVMT-Rx-4: A New Experimental Drug That May Help Block Prostate Cancer Spread to Bone

/in /by

IVMT-Rx-4 is a preclinical stage experimental compound being studied for advanced prostate cancer, especially for cancer that spreads to bone. The basic idea is to interfere with a protein called MDA-9/Syntenin. This protein seems to help prostate cancer cells invade tissue, communicate with their environment, and settle in bone. By blocking that pathway, IVMT-Rx-4 may […]

Read more

A Promising Drug Pair for Treatment-Resistant Prostate Cancer

/in , /by

A recent preclinical study points to a potentially important strategy for advanced prostate cancer: combining two already-known drugs to attack the disease from different angles at the same time. The work focused on metastatic castration-resistant prostate cancer, one of the hardest forms of prostate cancer to treat because it often adapts after standard hormonal therapies […]

Read more

Scientists Identify SIRT1 as a Driver of Neuroendocrine Prostate Cancer

/in , /by

Researchers have identified SIRT1 as a promising new target in neuroendocrine prostate cancer, a rare but highly aggressive subtype that often develops after standard hormone therapy stops working. The finding is important because this form of prostate cancer is especially hard to treat and tends to behave more aggressively than typical androgen-driven disease. The study […]

Read more

Telmisartan: A Familiar Blood Pressure Pill with New Potential in Cancer Therapy

/in , /by

Telmisartan, a widely used blood pressure drug, has shown unexpected promise as a booster for cancer treatment. Preclinical research indicates that when telmisartan is combined with the PARP inhibitor olaparib, cancer cells accumulate more DNA damage and become more vulnerable to treatment, even if they do not carry the usual BRCA‑type DNA repair defects that […]

Read more

DNA‑barcoded Gold Nanoparticles that Deliver Therapy Directly to Cancer Cell Mitochondria.

/in , /by

Cancer drugs often fail not because they are weak, but because they never reach the exact place they are supposed to act, all the way down to the tiny structures inside tumour cells. Researchers at the National University of Singapore have developed a new way to search for nanoparticles that can carry treatment directly to […]

Read more

Orlistat@Cys8E Nanoparticles: Remodeling Lipids to Kill Prostate Cancer

/in , /by

Orlistat is a well‑known weight‑loss drug that also blocks a key enzyme cancer cells use to make fats, and researchers have been trying to re‑use it against tumors for years. Recently a team developed a new way to deliver orlistat directly into prostate cancer cells by packing it inside tiny, engineered particles called Cys8E nanoparticles […]

Read more

Combining BCL-2 Inhibitors With Androgen Blockade May Prevent Castration Resistance

/in /by

Researchers at Roswell Park Comprehensive Cancer Center have identified a critical vulnerability in how prostate cancers escape standard hormonal therapy. The study reveals that when androgen receptor signaling is suppressed by ADT or AR pathway inhibitors, cancer cells compensate by ramping up BCL-2, an anti-apoptotic protein that helps them survive treatment. The findings suggest that […]

Read more